A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma.
- Author:
Fangfang YUAN
1
;
Xudong WEI
1
;
Qingsong YIN
1
;
Yufu LI
1
;
Ruihua MI
1
;
Hao AI
1
;
Haiping YANG
1
;
Hongyi LI
1
;
Shoubei GE
1
;
Yanyan LIU
1
;
Yongping SONG
1
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Asparaginase; administration & dosage; Cyclophosphamide; therapeutic use; Doxorubicin; therapeutic use; Female; Humans; Lymphoma, Extranodal NK-T-Cell; drug therapy; Male; Middle Aged; Prednisone; therapeutic use; Retrospective Studies; Treatment Outcome; Vincristine; therapeutic use
- From: Chinese Journal of Hematology 2014;35(7):614-618
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the short-term efficacy, overall survival (OS), and safety in newly diagnosed extranodal NK/T-cell lymphoma (ENKTL) patients with L-asparaginase based regimens or CHOP regimen in combination with radiotherapy as first-line treatment.
METHODSOf the total 181 patients diagnosed by imaging and pathology, 69 patients received CHOP regimen and 112 patients received L-asparaginase based regimens. All the patients received radical radiotherapy(RT)after 6 cycles of chemotherapy.
RESULTSThe overall response rates of L-asparaginase-based group and CHOP group were 90.2% and 72.5%, respectively (P=0.002). The 1, 2, 5-year OS and progression-free survival (PFS) in L-asparaginase-based group were 96.0%, 88.3%, 65.1% and 94.2%, 79.8%, 50.0%, respectively. The 1, 2, 5-year OS and PFS in CHOP group were 82.6%, 61.9%, 28.4% and 63.8%, 44.0%, 21.0% (P=0.000).
CONCLUSIONCompared with CHOP regimen, L-asparaginase-based chemotherapy is more effective and safe for newly diagnosed nasal-type ENKTL.
